D
Arcus Biosciences, Inc.
RCUS
$9.34
-$0.20-2.10%
D
Sell
8/15/2024Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index and total return index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index and total return index.
E
Sell
8/8/2024Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to E+ from D- on 8/8/2024 due to a decline in the volatility index.
Arcus Biosciences, Inc. (RCUS) was downgraded to E+ from D- on 8/8/2024 due to a decline in the volatility index.
D
Sell
7/19/2024Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D- from E+ on 7/19/2024 due to an increase in the volatility index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D- from E+ on 7/19/2024 due to an increase in the volatility index.
E
Sell
7/3/2024Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to E+ from D- on 7/3/2024 due to a decline in the volatility index, total return index and valuation index.
Arcus Biosciences, Inc. (RCUS) was downgraded to E+ from D- on 7/3/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
2/26/2024Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 2/26/2024 due to a decline in the efficiency index, solvency index and total return index. Net income declined 14.08% from -$71M to -$81M, and total capital declined 9.47% from $644M to $583M.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 2/26/2024 due to a decline in the efficiency index, solvency index and total return index. Net income declined 14.08% from -$71M to -$81M, and total capital declined 9.47% from $644M to $583M.
D
Sell
12/1/2023Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 12/1/2023 due to an increase in the solvency index, efficiency index and volatility index. Net income increased 5.33% from -$75M to -$71M.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 12/1/2023 due to an increase in the solvency index, efficiency index and volatility index. Net income increased 5.33% from -$75M to -$71M.
D
Sell
10/26/2023Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 10/26/2023 due to a decline in the volatility index and total return index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 10/26/2023 due to a decline in the volatility index and total return index.
D
Sell
9/22/2023Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 9/22/2023 due to an increase in the volatility index, total return index and valuation index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 9/22/2023 due to an increase in the volatility index, total return index and valuation index.
D
Sell
9/7/2023Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 9/7/2023 due to a decline in the volatility index and valuation index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 9/7/2023 due to a decline in the volatility index and valuation index.
D
Sell
8/8/2023Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 8/8/2023 due to an increase in the growth index, total return index and solvency index. Operating cash flow increased 41.84% from -$98M to -$57M, total revenue increased 16% from $25M to $29M, and earnings per share increased from -$1.0959 to -$1.0246.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 8/8/2023 due to an increase in the growth index, total return index and solvency index. Operating cash flow increased 41.84% from -$98M to -$57M, total revenue increased 16% from $25M to $29M, and earnings per share increased from -$1.0959 to -$1.0246.
D
Sell
5/16/2023Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 5/16/2023 due to a noticeable decline in the total return index, volatility index and growth index. Operating cash flow declined 40.52% from -$69.74M to -$98M, total revenue declined 25.72% from $33.66M to $25M, and earnings per share declined from -$0.9308 to -$1.0959.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 5/16/2023 due to a noticeable decline in the total return index, volatility index and growth index. Operating cash flow declined 40.52% from -$69.74M to -$98M, total revenue declined 25.72% from $33.66M to $25M, and earnings per share declined from -$0.9308 to -$1.0959.
D
Sell
3/2/2023Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D from C on 3/2/2023 due to a significant decline in the growth index, valuation index and efficiency index. EBIT declined 7.27% from -$69.4M to -$74.44M, total capital declined 5% from $817.9M to $777M, and net income declined 3.91% from -$64.92M to -$67.46M.
Arcus Biosciences, Inc. (RCUS) was downgraded to D from C on 3/2/2023 due to a significant decline in the growth index, valuation index and efficiency index. EBIT declined 7.27% from -$69.4M to -$74.44M, total capital declined 5% from $817.9M to $777M, and net income declined 3.91% from -$64.92M to -$67.46M.
C
Hold
11/3/2022Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to C from C- on 11/3/2022 due to a noticeable increase in the growth index, valuation index and total return index. Total revenue increased 25.49% from $26.76M to $33.58M, and earnings per share increased from -$0.9278 to -$0.8987.
Arcus Biosciences, Inc. (RCUS) was upgraded to C from C- on 11/3/2022 due to a noticeable increase in the growth index, valuation index and total return index. Total revenue increased 25.49% from $26.76M to $33.58M, and earnings per share increased from -$0.9278 to -$0.8987.
C
Hold
8/4/2022Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to C- from D+ on 8/4/2022 due to a substantial increase in the growth index, efficiency index and valuation index. Total revenue increased 48.62% from $18.01M to $26.76M, earnings per share increased from -$0.955 to -$0.9278, and net income increased 2% from -$67.99M to -$66.63M.
Arcus Biosciences, Inc. (RCUS) was upgraded to C- from D+ on 8/4/2022 due to a substantial increase in the growth index, efficiency index and valuation index. Total revenue increased 48.62% from $18.01M to $26.76M, earnings per share increased from -$0.955 to -$0.9278, and net income increased 2% from -$67.99M to -$66.63M.
D
Sell
5/10/2022Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D+ from C on 5/10/2022 due to a significant decline in the growth index, solvency index and efficiency index. Earnings per share declined from $3.6998 to -$0.955, net income declined 124.34% from $279.37M to -$67.99M, and EBIT declined 123.88% from $281.27M to -$67.18M.
Arcus Biosciences, Inc. (RCUS) was downgraded to D+ from C on 5/10/2022 due to a significant decline in the growth index, solvency index and efficiency index. Earnings per share declined from $3.6998 to -$0.955, net income declined 124.34% from $279.37M to -$67.99M, and EBIT declined 123.88% from $281.27M to -$67.18M.
C
Hold
5/6/2022Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to C from C- on 5/6/2022 due to an increase in the valuation index.
Arcus Biosciences, Inc. (RCUS) was upgraded to C from C- on 5/6/2022 due to an increase in the valuation index.
C
Hold
4/18/2022Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to C- from C on 4/18/2022 due to a decline in the total return index and valuation index.
Arcus Biosciences, Inc. (RCUS) was downgraded to C- from C on 4/18/2022 due to a decline in the total return index and valuation index.
C
Hold
2/28/2022Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to C from D on 2/28/2022 due to a significant increase in the growth index, efficiency index and solvency index. Total revenue increased 3,646.95% from $9.46M to $354.5M, EBIT increased 459.97% from -$78.14M to $281.27M, and net income increased 458.28% from -$77.98M to $279.37M.
Arcus Biosciences, Inc. (RCUS) was upgraded to C from D on 2/28/2022 due to a significant increase in the growth index, efficiency index and solvency index. Total revenue increased 3,646.95% from $9.46M to $354.5M, EBIT increased 459.97% from -$78.14M to $281.27M, and net income increased 458.28% from -$77.98M to $279.37M.
D
Sell
2/24/2022Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 2/24/2022 due to a large decline in the total return index and valuation index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 2/24/2022 due to a large decline in the total return index and valuation index.
D
Sell
2/8/2022Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 2/8/2022 due to an increase in the valuation index and volatility index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 2/8/2022 due to an increase in the valuation index and volatility index.
D
Sell
11/9/2021Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 11/9/2021 due to an increase in the total return index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 11/9/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index.
D
Sell
11/3/2021Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 11/3/2021 due to a decline in the solvency index and valuation index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 11/3/2021 due to a decline in the solvency index and valuation index.
D
Sell
10/12/2021Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 10/12/2021 due to a noticeable increase in the total return index and valuation index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 10/12/2021 due to a noticeable increase in the total return index and valuation index.
D
Sell
9/21/2021Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 9/21/2021 due to a decline in the total return index and valuation index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 9/21/2021 due to a decline in the total return index and valuation index.
D
Sell
5/7/2021Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 5/7/2021 due to an increase in the valuation index, total return index and volatility index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 5/7/2021 due to an increase in the valuation index, total return index and volatility index.
D
Sell
1/20/2021Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 1/20/2021 due to a decline in the valuation index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 1/20/2021 due to a decline in the valuation index.
D
Sell
1/5/2021Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 1/5/2021 due to a noticeable increase in the total return index and valuation index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 1/5/2021 due to a noticeable increase in the total return index and valuation index.
D
Sell
12/21/2020Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 12/21/2020 due to a noticeable decline in the solvency index, valuation index and volatility index. The quick ratio declined from 11.57 to 4.82.
Arcus Biosciences, Inc. (RCUS) was downgraded to D from D+ on 12/21/2020 due to a noticeable decline in the solvency index, valuation index and volatility index. The quick ratio declined from 11.57 to 4.82.
D
Sell
8/7/2020Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 8/7/2020 due to a noticeable increase in the solvency index, valuation index and total return index. The quick ratio increased from 7.53 to 11.57.
Arcus Biosciences, Inc. (RCUS) was upgraded to D+ from D on 8/7/2020 due to a noticeable increase in the solvency index, valuation index and total return index. The quick ratio increased from 7.53 to 11.57.
D
Sell
5/4/2020Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 5/4/2020 due to an increase in the total return index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 5/4/2020 due to an increase in the total return index.
D
Sell
4/17/2020Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 4/17/2020 due to a decline in the valuation index and solvency index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 4/17/2020 due to a decline in the valuation index and solvency index.
D
Sell
3/23/2020Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 3/23/2020 due to an increase in the valuation index, total return index and volatility index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 3/23/2020 due to an increase in the valuation index, total return index and volatility index.
D
Sell
3/6/2020Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 3/6/2020 due to a decline in the valuation index, efficiency index and solvency index. The quick ratio declined from 9.32 to 8.3, and total capital declined 7.55% from $177.23M to $163.84M.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 3/6/2020 due to a decline in the valuation index, efficiency index and solvency index. The quick ratio declined from 9.32 to 8.3, and total capital declined 7.55% from $177.23M to $163.84M.
D
Sell
11/6/2019Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 11/6/2019 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.6414 to -$0.51, and EBIT increased 20.27% from -$29.16M to -$23.25M.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 11/6/2019 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.6414 to -$0.51, and EBIT increased 20.27% from -$29.16M to -$23.25M.
D
Sell
10/29/2019Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 10/29/2019 due to a decline in the volatility index.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 10/29/2019 due to a decline in the volatility index.
D
Sell
10/10/2019Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 10/10/2019 due to an increase in the growth index, volatility index and valuation index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 10/10/2019 due to an increase in the growth index, volatility index and valuation index.
D
Sell
7/17/2019Downgrade
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 7/17/2019 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 136.94% from -$7.11M to -$16.84M, earnings per share declined from -$0.2848 to -$0.4061, and EBIT declined 39.22% from -$13.48M to -$18.77M.
Arcus Biosciences, Inc. (RCUS) was downgraded to D- from D on 7/17/2019 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 136.94% from -$7.11M to -$16.84M, earnings per share declined from -$0.2848 to -$0.4061, and EBIT declined 39.22% from -$13.48M to -$18.77M.
D
Sell
4/1/2019Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 4/1/2019 due to an increase in the valuation index.
Arcus Biosciences, Inc. (RCUS) was upgraded to D from D- on 4/1/2019 due to an increase in the valuation index.
D
Sell
12/3/2018Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to D- from E on 12/3/2018 due to a noticeable increase in the growth index, solvency index and valuation index. Total revenue increased 243.28% from $1.25M to $4.29M, EBIT increased 23.61% from -$15.9M to -$12.15M, and earnings per share increased from -$0.3182 to -$0.2524.
Arcus Biosciences, Inc. (RCUS) was upgraded to D- from E on 12/3/2018 due to a noticeable increase in the growth index, solvency index and valuation index. Total revenue increased 243.28% from $1.25M to $4.29M, EBIT increased 23.61% from -$15.9M to -$12.15M, and earnings per share increased from -$0.3182 to -$0.2524.
E
Sell
9/4/2018Upgraded
Arcus Biosciences, Inc. (RCUS) was upgraded to E from E- on 09/04/2018.
Arcus Biosciences, Inc. (RCUS) was upgraded to E from E- on 09/04/2018.
E
Sell
8/7/2018None
Arcus Biosciences, Inc. (RCUS) was downgraded to E- from U on 08/07/2018.
Arcus Biosciences, Inc. (RCUS) was downgraded to E- from U on 08/07/2018.
NYSE
03/14/2025 4:00PM Eastern
Quotes delayed
